- Journal Archives
- Volume 20
- Volume 19
- Volume 18
- Volume 17
- Volume 16
- Volume 15
- Volume 14
- Volume 13
- Volume 12
- Volume 11
- Volume 10
- Volume 9
- Volume 8
- Volume 7
- Volume 6
- Volume 5
- Volume 4
- Volume 3
- Volume 2
- Volume 1
- 2017-2018 Symposium
- 2016-2017 Symposium
- 2015-2016 Symposium
- 2014-2015 Symposium
- 2013-2014 Symposium
- 2012-2013 Symposium
- 2011-2012 Symposium
- 2010-2011 Symposium
- 2009-2010 Symposium
- 2008-2009 Symposium
- 2007-2008 Symposium
Currently viewing the tag: "pharmaceuticals"
On September 14, 2015 By Rachel Conry September 13, 2015
In a number of recent cases, the Supreme Court has taken on the pharmaceutical industry, resulting in decisions with important implications for plaintiffs, drug manufacturers, and Americans who purchase pharmaceutical drugs.
On February 22, the Court held in Bruesewitz et al. v. Wyeth Inc. that the National Childhood Vaccine Injury Act of 1986, [...]Continue Reading →
In the news . . .
Google and NSA team up to fight cyberattacks.
Scientists discover energy teleportation.
Seventh Circuit upholds prison ban on Dungeons & Dragons against First and Fourteenth Amendment challenge.Continue Reading →
I respect the time, effort, and money that pharmaceutical companies devote to drug research and development, and advertising the drugs that are ultimately developed is an inevitable part of the research and development [...]Continue Reading →
Most people agree that a generic biologics pathway for the U.S. Food and Drug Administration (FDA) approval of these drugs would be a boon to consumers, but different parties seem to be at odds on the exact exclusivity period that the pharmaceutical companies should be given from their generic drug competitors.
These generic biologics [...]Continue Reading →
Sometimes it’s hard to have a lot of faith in the FDA– especially in light of recent reports that the Georgia peanut plant at the heart of salmonella-related deaths was home to roaches and other goodies. Well, last week the FDA approved the use of dairy goats by drug manufacturers. The goats [...]Continue Reading →
On October 7, 2008 By JETLaw October 7, 2008
Pfizer, Inc., the world’s largest research-based pharmaceutical company, announced on October 1 that it plans to discontinue research and development in the areas of heart disease, cholesterol, obesity and bone health. The company predicated its decision on the scheduled 2011 expiration of the company’s patent for its bestselling, cholesterol-reducing drug, Lipitor. Research and [...]Continue Reading →
Recent Blog Posts
- Uber Settles IP Dispute after Embattled Former CEO Takes the Stand at Trial
- The Role of the Statute of Limitations in the Harvey Weinstein Saga
- Misusing Mickey Mouse: The Fight Over Movie Download Codes
- Songwriter’s Revocation: How Writers Gain Freedom After 35 Years
- Recapping JETLaw’s 2018 Symposium!
- Taking a Gamble: New Jersey Sports Betting and the Supreme Court
Tagsadvertising antitrust Apple books career celebrities contracts copyright copyright infringement courts creative content criminal law entertainment Facebook FCC film/television financial First Amendment games Google government intellectual property internet JETLaw journalism lawsuits legislation media medicine Monday Morning JETLawg music NFL patents privacy progress publicity rights radio social networking sports Supreme Court of the United States (SCOTUS) technology telecommunications trademarks Twitter U.S. Constitution